- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00931515
Trial Evaluating the Safety and Effectiveness of NUBAC™ Disc Arthroplasty
A Prospective, Multi-center, Randomized, Controlled Clinical Trial Evaluating the Safety and Effectiveness of NUBAC™ Disc Arthroplasty
The NuBac device is indicated for reconstruction following nucleotomy in skeletally mature patients at least 18 years of age with symptomatic single level degenerative disc disease (DDD) at L4/L5 only.
DDD is defined as discogenic back pain with or without leg pain; with degeneration of the disc as confirmed by patient history, physical examination, radiographic studies showing: decreased disc height, contained herniated nucleus, vacuum phenomenon (dark disc) OR positive discography at the affected level.
These DDD patients should have no more than Grade 1 spondylolisthesis at the involved level and should have failed at least six months of conservative, non-operative care.
Demonstrate non-inferiority compared to ProDisc.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
STUDY DESIGN:
Multicenter, prospective, randomized (1:1), controlled study comparing the artificial nucleus to ProDisc. After implanting artificial nucleus in two patients during the training session, enrollment of randomized patients shall begin. The study is expected to be completed in four years.
NUMBER OF INVESTIGATIONAL SITES and INVESTIGATORS:
10 - 20 investigational sites, 1 to 2 investigators per site, approximately 20-40 patients per site
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Beverly Hills, California, United States, 90211
- Spine Group Beverly Hills
-
Beverly Hills, California, United States, 90211
- Tower Orthopedics & Sports Medicine
-
Colton, California, United States, 92324
- Bergey Spine Institute
-
Loma Linda, California, United States, 92354
- Loma Linda University - Faculty Physicians
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado, Anschutz Outpatient Pavilion
-
Loveland, Colorado, United States, 80538
- The Spine Institute
-
-
Florida
-
Tampa, Florida, United States, 33637
- Florida Orthopaedic Institute
-
-
Illinois
-
Oak Lawn, Illinois, United States, 60453
- Bone & Joint Physicians
-
-
Kansas
-
Merriam, Kansas, United States, 66204
- Heartland Hand & Spine Orthopedic Center
-
-
Michigan
-
Marquette, Michigan, United States, 49855
- Orthopaedic Surgical Associates
-
-
Missouri
-
St. Louis, Missouri, United States, 63017
- The Orthopedic Center of St. Louis
-
-
New York
-
Buffalo, New York, United States, 14224
- Buffalo Neurosurgery
-
Johnson City, New York, United States, 13790
- Southern New York NeuroSurgical Group
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28204
- Carolina Neurosurgery and Spine Associates
-
-
Oregon
-
Eugene, Oregon, United States, 97401
- Neurospine Institute
-
-
Tennessee
-
Bristol, Tennessee, United States, 37620
- Neurospine Solutions, PC
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53211
- Milwaukee Spinal Specialists
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- is at least 18 years of age and skeletally mature
- must have symptomatic single level degenerative disc disease at L4/5 requiring surgical treatment
- must have completed a minimum of six months of unsuccessful conservative, non-operative care
- must have discogenic back pain with or without leg pain
- must show radiographic confirmation using plain films, MRI, CT, myelogram or discography of one of the following: decreased disc height when compared to the adjacent level, contained herniated nucleus, or vacuum phenomenon (dark disc)
- must score at least 40% on the Oswestry Disability Index
- must score at least 4 on a 10cm Visual Analog Scale for back pain
- is able to comply with the protocol's follow-up schedule
- must understand and sign the informed consent document
Exclusion Criteria:
- symptomatic DDD at more than one level
- previous fusion at any lumbar level or laminectomy at the target level (discectomy, Intradiscal Electrothermal Annuloplasty, laminotomy, or nucleolysis performed > 6 months ago are permitted)
- clinically compromised vertebral bodies, at the affected level due to previous trauma, i.e., compression or burst fracture
- pars defect
- involved vertebral endplate dimensionally smaller than 34.5 mm in the medial-lateral direction and/or 27 mm in the anterior-posterior direction
- disc height less than 5 mm at the target level
- bony stenosis
- lytic spondylolisthesis, spondylolisthesis greater than 3mm
- lumbar scoliosis greater than 11 degrees.
- osteoporosis, osteopenia, osteomalacia, Paget's disease or metabolic bone disease
- Schmorl's nodes, an incomplete annulus, or endplates that are not intact
- spinal tumors
- symptomatic facet joint disease
- free fragment herniation confirmed radiographically
- isolated radicular compression syndrome, especially due to a disc herniation
- arachnoiditis
- active infection or surgical site infection
- is using any medication known to interfere with bone/soft tissue healing
- rheumatoid arthritis or other autoimmune disease
- systemic disease such as AIDS, HIV, hepatitis
- morbid obesity defined as body mass index (BMI) >40 or a weight more than 100 lbs over ideal body weight
- psychosocial disorders that would preclude accurate evaluation or has a history of substance abuse
- active malignancy except non-melanoma skin cancer; history of any invasive malignancy unless treated and in remission for at least five years
- documented allergies to metal or plastic; i.e., cobalt, chromium, molybdenum, polyethylene, titanium or polyetheretherketone
- pregnancy, or interested in becoming pregnant within the next two years
- prisoner
- involvement in an investigational drug or device study within 30 days
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: NuBac
NuBac device implanted at the L4/5 level
|
NuBac device implanted at the L4/5 level.
Other Names:
|
ACTIVE_COMPARATOR: Prodisc-L
Prodisc-L implanted at the L4/5 level.
|
Prodisc-L implanted at the L4/5 level.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Participants With Improved Patient Function
Time Frame: 24 months
|
The comparison of results was based on the proportion of participants with improved outcomes. The primary efficacy variable was treatment success based on the following criteria:
|
24 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Matthew Songer, MD, Orthopedic Surgery Associates
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- N012009
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Degenerative Disc Disease
-
Assistance Publique - Hôpitaux de ParisTerminatedCervical Degenerative Disc Disease | Kyphosis | Lumbar Degenerative Disc DiseaseFrance
-
Assiut UniversityNot yet recruiting
-
Spine BioPharma, IncMCRARecruitingLumbar Degenerative Disc DiseaseUnited States
-
AxioMed Spine CorporationUnknownDegenerative Disc Disease (DDD)United States, Germany
-
Synthes USA HQ, Inc.CompletedLumbar Degenerative Disc Disease
-
DePuy InternationalTerminatedCervical Degenerative Disc DiseaseAustralia, Germany, Italy, Malaysia, Netherlands, Spain, United Kingdom
-
Synergy Spine SolutionsMCRARecruitingCervical Degenerative Disc DiseaseUnited States
-
Orthofix Inc.TerminatedCervical Degenerative Disc DiseaseUnited States
-
Yuhan CorporationCompletedDisc Degenerative DiseaseKorea, Republic of
-
Synergy Spine SolutionsMCRANot yet recruitingCervical Degenerative Disc DiseaseUnited Kingdom